Entyvio Safe, Effective for Ulcerative Colitis and Crohn’s, Studies Show

Entyvio Safe, Effective for Ulcerative Colitis and Crohn’s, Studies Show
Entyvio (vedolizumab) is safe and effective to treat adults with moderate-to-severe active ulcerative colitis (UC) and Crohn's disease (CD). These results come from eight real-world analyses presented by Takeda Pharmaceutical Company at 2017 Digestive Disease Week conference in Chicago, Illinois, May 6-9. Two analyses conducted by the U.S. VICTORY (Vedolizumab for Health OuTComes in InflammatORY Bowel Diseases) consortium, a partnership of 10 leading IBD centers from across the U.S.. support the efficacy of Entyvio. The consortium now includes in its database information from about 900 UC and CD patients taking Entyvio in a real-world setting in the U.S. The efficacy of Entyvio is supported by findings from the pivotal GEMINI clinical trial program. Data from GEMINI Phase 3 trial, which started in May 2009 and is expected to be complete in July 2017, indicate that patients responding to long-term treatment with Entyvio exhibited clinical response and remission. Patients also improved their health-related quality of life. The study enrolled 146 patients with CD and 154 patients with UC who were part of the GEMINI II (NCT00783692) and GEMINI I (NCT00783718) studies. Also part of the program is the GEMINI III (NCT01224171) study, which enrolled about 416 patients with moderate-to-severe CD. One of the analyses presented during the Digestive Disease Week meeting examined clinical response and remission, and steroid-free response and remission, in 180 patients with
Subscribe or to access all post and page content.